INL Cluster

Innovative Microfluidic Platform for Analysis of myeloid Leukemia blasts mielóide

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults that, although having favourable outcomes for younger patients upon receiving treatment, has a very poor prognosis in the elderly. After treatment with chemotheraphy, even patients that clinically achieve complete remission (CR) can relapse through the persistence of minimal residual disease (MRD), with fatal consequences. The low sensitivity of current diagnostic technologies based on flow cytometry and bone marrow biopsy often prevents early MRD detection, while being highly invasive and costly. Accurate and early diagnosis of MRD would allow the application of appropriate theraphy, improving the prognosis of the patients. Thus, the scope of this project is to discover new biomarkers of AML through Next Generation Sequencing, and to design, fabricate, test and optimize new lab-on-a-chip (LOC) systems based on Surface Enhanced Raman Scattering (SERS) and microfluidics for early detection of MRD in AML.

Total Eligible Budget

237,556.40 €

INL Eligible Budget

213,556.40 €

INL Funding

213,556.40 €

Start Date


End Date


Type of action

SAICT – Projetos de investigação cientifica e desenvolvimento tecnológico (IC&DT)

Grant Agreement Id


Funding Framework


INL Role


Approval Date